Rain Oncology Inc reports results for the quarter ended in December - Earnings Summary

Rain Oncology

09/03/2023 22:55

* Rain Oncology Inc  RAIN.OQ  reported a quarterly adjusted
loss
of 70 cents​​ per share for the quarter ended in December. The
mean expectation of ten analysts for the quarter was for a loss
of 56 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Rain Oncology Inc's reported EPS for the quarter was a
loss
of 70 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Rain Oncology Inc shares had risen by 15.5% this quarter.
    * The company reported a quarterly loss of $22.68 million.
    * Wall Street's median 12-month price target for Rain
Oncology Inc
is $17.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 9 at 10:54 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.56          -0.70          Missed
 Sep. 30 2022      -0.69          -0.68          Beat
 Jun. 30 2022      -0.66          -0.66          Met
 Mar. 31 2022      -0.70          -0.66          Beat